Immunome (IMNM) Operating Leases (2023 - 2026)

Immunome's Operating Leases history runs 4 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• Quarterly Operating Leases fell 22.56% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 22.56% YoY) and the FY2025 annual result came in at $3.9 million, down 19.17% from the prior year.
• Operating Leases was $3.7 million for Q1 2026 at Immunome, down from $3.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $4.8 million in Q1 2025 and bottomed at $1.2 million in Q1 2024.
• A 4-year average of $3.1 million and a median of $3.7 million in 2026 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases surged 295.52% — and 2026, when it fell 22.56%.
• Immunome's Operating Leases stood at $1.3 million in 2023, then soared by 255.9% to $4.8 million in 2024, then slipped by 19.17% to $3.9 million in 2025, then slipped by 4.18% to $3.7 million in 2026.
• Business Quant data shows IMNM's Operating Leases at $3.7 million in Q1 2026, $3.9 million in Q4 2025, and $4.0 million in Q3 2025.